Table 3.

Secondary outcome data for anakinra 50–150 mg compared to placebo.

Mean at BaselineMean Difference (Confidence intervals)Relative Change from Baseline*Studies Providing Data
Change in HAQ1.49−0.19 (−0.30, −0.09)0.13Bresnihan 199833
Cohen 200436
Change in VAS (pain)0.64−0.10 (−0.15, −0.04)0.16Bresnihan 199833
Change in Larsen scores13.5−2.45 (−4.53, −0.36)0.18Bresnihan 199833
Change in ESR45.97−10.04 (−12.75, −7.33)0.22Bresnihan 199833
Cohen 200436
Change in CRP4.1−0.6 (−1.26, 0.06)0.15Bresnihan 199833
  • Data exclude outcome data from Genovese 200437.

  • * Relative change from baseline = mean difference/mean at baseline. HAQ: Health Assessment Questionnaire; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.